INOpulse Shows Promise in Proof-of-concept Trial for PH-Sarcoidosis

INOpulse Shows Promise in Proof-of-concept Trial for PH-Sarcoidosis

315780

INOpulse Shows Promise in Proof-of-concept Trial for PH-Sarcoidosis

INOpulse, a device that administers inhaled nitric oxide, significantly improved blood flow parameters in a small proof-of-concept clinical trial conducted in people with pulmonary hypertension associated with sarcoidosis (PH-Sarc). “We are pleased with the positive top-line data from this proof-of-concept study,” Naseem Amin, MD, chairman of the board of directors at Bellerophon Therapeutics, said in a press release. Bellerophon is the company developing INOpulse. “Based on these results, Bellerophon is working with its steering committee, which…

You must be logged in to read/download the full post.